Trial · NCT01882010
Leukine (Sargramostim) for Parkinson's Disease
NCT01882010, Phase 1, Completed, University of Nebraska
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Leukine (Sargramostim) for Parkinson's Disease. Trials, record NCT01882010. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01882010
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Leukine (Sargramostim) for Parkinson's Disease
- NCT number
- NCT01882010
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 37 participants, actual
- Lead sponsor
- University of Nebraska
- Conditions
- Parkinson's Disease
- Interventions
- sargramostim, placebo, Sham Comparator: Controls
- First posted
- 2013-06-20
- Last updated
- 2023-10-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of adverse events | 52 weeks | An adverse event is defined as any undesirable physical, psychological, or behavioral effect experienced by a patient in conjunction with the use of the study drug. |
| Secondary | Change in UPDRS part III score | -8, -4, 0, +2, +4, +6, +8, +12 weeks | Score from part III motor examination of the Unified Parkinson's Disease Rating Scale Score Sheet. |
| Secondary | Change in blood analyses results | -8, -4, 0, +2, +4, +6, +8, +12 weeks | Comprehensive metabolic panel, complete blood count with white blood cell differential (CBC/dif), and total T cell (lymphocyte) counts blood analyses |
| Secondary | Abnormal findings in physical examination | -8, -4, 0, +2, +4, +6, +8, +12 weeks | Physical examination including temperature, blood pressure, pulse, and skin, lung, liver, heart, and abdomen assessments. |
| Secondary | Change in FACS results | -8, -4, 0, +2, +4, +6, +8, +12 weeks | T cell markers analyzed by fluorescence-activated cell sorting. |
| Secondary | Change in function of Treg cells | -8, -4, 0, +2, +4, +6, +8, +12 weeks | Regulatory T cells isolated from peripheral blood are tested for their ability to suppress proliferation of activated T cells. |
| Secondary | Change in magnetoencephalography (MEG) results | 0, +8, +12 weeks | Magnetoencephalography measurements during behavioral tasks |
| Other | Change in Motion Analysis | -4, +8, +12 weeks | Motion analysis including biomechanical assessments of the subject's mobility, postural balance, upper extremity motor control and resting state tremor. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01NS034239 | Neuroprotective Immunity and HIV Dementia | GENDELMAN, HOWARD E; MOSLEY, R LEE | UNIVERSITY OF NEBRASKA MEDICAL CENTER | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 1995 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01882010
GET https://conductscience.org/api/trials/v1/NCT01882010/registered